AVEO Pharmaceuticals Inc

+0.02 (+0.26%)
Earnings Announcements

Aveo Oncology - QTRLY Net Loss Of $0.24 Per Basic And Diluted Share

Published: 08/04/2022 21:28 GMT
AVEO Pharmaceuticals Inc (AVEO) - Aveo Oncology Reports Second Quarter 2022 Financial Results.
Aveo Oncology - Total Q2 2022 Net Revenue of $25.3 Million.
Aveo Oncology - Qtrly Net Loss of $0.24 per Basic and Diluted Share.
Q2 Earnings per Share View $-0.28, Revenue View $25.3 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $29.42 Million
Adjusted EPS is expected to be -$0.18

Next Quarter Revenue Guidance is expected to be $34.48 Million
Next Quarter EPS Guidance is expected to be -$0.11

More details on our Analysts Page.